Subsequently, we attempted to construct therapeutic nanocomplexes encapsulating siRNA-SEC14L3 within lipid nanoparticles externally bound to the targeted antibody MUC12 [38] for treating ccRCC, as illustrated in Fig. 6g. This evidence concerns the gene MUC12 and nonpapillary renal cell carcinoma.